US EditionLupin Strengthens Its Global Specialty Ophthalmology Business with Acquisition of VISUfarma From GHO Capital
- Drugmaker Lupin will acquire Dutch firm VISUfarma for an enterprise value of euro 190 million.
- The acquisition is expected to be completed by December and will be financed through internal accruals.
- Lupin's presence in Europe will be enhanced by the acquisition, which will expand its specialty portfolio with over 60 branded ophthalmology products.
- VISUfarma reported consolidated revenue of euro 48.1 million in 2024, indicating a robust financial position.
34 Articles
34 Articles
keenesentinel.com
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the…
Times of India
Lupin subsidiary inks pact to acquire Netherlands-based VISUfarma
Lupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. The acquisition strengthens Lupin's specialty franchise. It will enter the ophthalmology market. The deal is expected to close by late 2025. This transaction will enhance Lupin's growth and margin profile.
Lupin Acquires VISUfarma to Expand Ophthalmology Portfolio Across Europe
Global Healthcare Opportunities, or GHO Capital Partners, has announced the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to Lupin Limited. VISUfarma was formed in 2016 when GHO Capital combined the founder-owned Italian VISUfarma with the European commercial operations of Nicox SA. Under GHO’s ownership, VISUfarma has grown into a pan-European leader with operations in Italy, the United Kingdom, Spain, Germany,…
GHO Capital sells VISUfarma to Lupin
LONDON — Global Healthcare Opportunities, the European specialist investor in global healthcare, is delighted to announce the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin Limited (Lupin).VISUfarma was created by GHO Capital in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A. Since its initial investment as part of Fund I, GH…
Lupin acquires VISUfarma to strengthen ophthalmology business - Express Pharma
Lupin’s wholly owned subsidiary, Nanomi B.V. (‘Nanomi’), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners LLP (GHO). The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin’s strategy to expand its European business and footprint and to…
Coverage Details
Bias Distribution
- 42% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
